[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 939
Citations 0
News From the Food and Drug Administration
July 7, 2015

Diabetes Drug Warning

JAMA. 2015;314(1):17. doi:10.1001/jama.2015.6849

Several drugs approved to treat type 2 diabetes may lead to ketoacidosis, a serious condition that may require hospitalization, the FDA has warned.

The medications named in the safety announcement—canagliflozin, dapagliflozin, and empagliflozin—belong to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class of drugs that are FDA-approved for use with diet and exercise to lower blood glucose levels in adults with type 2 diabetes. The SGLT2 inhibitors lower blood glucose levels by causing the kidneys to remove glucose from the body through urine.

First Page Preview View Large
First page PDF preview
First page PDF preview